Skip to content
ISSAR Pharma

ISSAR Pharma

  • About Us
    • Our DNA
    • Our new identity
    • Our history
    • Our People
    • Our Vision,Mission Values
    • Careers
  • Our Capabilities
    • Why Peptides ?
    • Services
    • Drug discovery and reseach
    • Formulation
    • Technology Capabilities
    • Manufacturing facility
    • Publications
    • Pipeline
  • Therapeutic Areas
    • Dermatology
    • Oncology
    • Gastroenterology
    • Bones & Joints
  • Brands
    • Novoskin®
    • Xylentra®
  • Patents
  • Compliance
Search

Category: Featured Article

Featured Article

Psoriasis patients undergoing biologic/other systemic therapies may experience mild SARS-CoV-2 infection Dermatology Featured Article Psoriasis

Psoriasis patients undergoing biologic/other systemic therapies may experience mild SARS-CoV-2 infection

October 28, 2021October 28, 2021root

Psoriasis patients undergoing biologic/other systemic therapies may experience mild SARS-CoV-2 infection A recent study published in the ‘Medicina’ Journal by the Multidisciplinary Digital Publishing Institute (MDPI), indicated that patients with…Continue readingPsoriasis patients undergoing biologic/other systemic therapies may experience mild SARS-CoV-2 infection

Leave a Comment on Psoriasis patients undergoing biologic/other systemic therapies may experience mild SARS-CoV-2 infection
CXCL9: A biomarker for Vitiligo activity Dermatology Featured Article Vitiligo

CXCL9: A biomarker for Vitiligo activity

October 12, 2021October 26, 2021root

CXCL9: A biomarker for Vitiligo activity A recent study published in the ‘Nature’ scientific journal, proposed that the CXCL9 gene is a key biomarker for vitiligo activity and a significant predictor of…Continue readingCXCL9: A biomarker for Vitiligo activity

Leave a Comment on CXCL9: A biomarker for Vitiligo activity
ISSAR’s Novel Peptide Drug for Rheumatoid Arthritis Bone and Joint Featured Article

ISSAR’s Novel Peptide Drug for Rheumatoid Arthritis

September 6, 2021September 8, 2021root

Rheumatoid Arthritis (RA) In a Global Burden of Disease (GBD) study conducted in the year 2010, which studied 291 conditions, Rheumatoid Arthritis (RA) was observed to be the 42nd highest…Continue readingISSAR’s Novel Peptide Drug for Rheumatoid Arthritis

Leave a Comment on ISSAR’s Novel Peptide Drug for Rheumatoid Arthritis
Novoskin- Improved peptide for Vitiligo treatment Featured Article Vitiligo

Novoskin- Improved peptide for Vitiligo treatment

September 6, 2021September 29, 2021root

The global prevalence rate of vitiligo ranges between 0.4%-3%, affecting individuals of all ages, races, and genders. Vitiligo treatment market dynamics Combination treatment therapies contribute to the majority of the…Continue readingNovoskin- Improved peptide for Vitiligo treatment

Leave a Comment on Novoskin- Improved peptide for Vitiligo treatment
ISSAR’s IS-217 for Inflammatory Bowel Diseases Featured Article Gastroenterology

ISSAR’s IS-217 for Inflammatory Bowel Diseases

September 6, 2021September 29, 2021root

Inflammatory Bowel Diseases (IBD) currently affect approximately 0.5% of the Western world’s population. The globally occurring cases increased from 3.7 million to over 6.8 million between the years 1990 to 2017.…Continue readingISSAR’s IS-217 for Inflammatory Bowel Diseases

Leave a Comment on ISSAR’s IS-217 for Inflammatory Bowel Diseases
ISSAR’s Dual Acting Anti-Psoriatic Molecule for Psoriasis Featured Article Psoriasis

ISSAR’s Dual Acting Anti-Psoriatic Molecule for Psoriasis

September 6, 2021September 8, 2021root

The global prevalence of psoriasis ranges between 0.09% to 11.14 %. Psoriasis affects >120 million worldwide, with no cure till date. The global psoriasis treatment market reached $20.19 billion in…Continue readingISSAR’s Dual Acting Anti-Psoriatic Molecule for Psoriasis

Leave a Comment on ISSAR’s Dual Acting Anti-Psoriatic Molecule for Psoriasis
Fixed-Dose Combination of Calcipotriol and Betamethasone is Effective in Patients with Psoriasis Vulgaris Dermatology Featured Article Psoriasis

Fixed-Dose Combination of Calcipotriol and Betamethasone is Effective in Patients with Psoriasis Vulgaris

July 26, 2021September 8, 2021root

A recent study published in the Journal of the European Academy of Dermatology and Venereology (JEADV), proposed that treatment of psoriasis vulgaris with calcipotriol (Cal) and betamethasone propionate (BD) foam…Continue readingFixed-Dose Combination of Calcipotriol and Betamethasone is Effective in Patients with Psoriasis Vulgaris

Leave a Comment on Fixed-Dose Combination of Calcipotriol and Betamethasone is Effective in Patients with Psoriasis Vulgaris
A Combination Treatment of Light Therapy and Topical Therapy is Effective in Acral Vitiligo Dermatology Featured Article Vitiligo

A Combination Treatment of Light Therapy and Topical Therapy is Effective in Acral Vitiligo

July 26, 2021September 8, 2021root

A recent study published in the Journal of Dermatologic Therapy suggested that a combination of excimer light and topical calcipotriol is effective in the treatment of acral vitiligo (vitiligo involving…Continue readingA Combination Treatment of Light Therapy and Topical Therapy is Effective in Acral Vitiligo

Leave a Comment on A Combination Treatment of Light Therapy and Topical Therapy is Effective in Acral Vitiligo
I.V. Methylprednisolone Pulse Therapy (IVMP) Is Safe and Effective for Progressive Generalised Vitiligo Dermatology Featured Article Vitiligo

I.V. Methylprednisolone Pulse Therapy (IVMP) Is Safe and Effective for Progressive Generalised Vitiligo

July 20, 2021September 8, 2021root

A recent study published in the Journal of Dermatology proposed that Intravenous Methylprednisolone Pulse therapy (IVMP) is a safe and effective treatment for progressive generalised vitiligo. The main aim of…Continue readingI.V. Methylprednisolone Pulse Therapy (IVMP) Is Safe and Effective for Progressive Generalised Vitiligo

Leave a Comment on I.V. Methylprednisolone Pulse Therapy (IVMP) Is Safe and Effective for Progressive Generalised Vitiligo
Systemic Corticosteroids Less Likely to Cause Severe Flares in Patients With a History of Psoriasis Dermatology Featured Article Psoriasis

Systemic Corticosteroids Less Likely to Cause Severe Flares in Patients With a History of Psoriasis

July 20, 2021September 8, 2021root

A recent study published in the Journal of the American Medical Association (JAMA), Dermatology reported that administration of systemic corticosteroids showed lesser rates of severe psoriasis flares in patients with…Continue readingSystemic Corticosteroids Less Likely to Cause Severe Flares in Patients With a History of Psoriasis

Leave a Comment on Systemic Corticosteroids Less Likely to Cause Severe Flares in Patients With a History of Psoriasis

Posts navigation

Older posts
Copyright © 2023 ISSAR Pharma | JetBlack by Firefly Themes
Scroll Up
This website uses cookies to help us give you the best experience when you visit. By using this website you consent to our use of cookies. For more information please review our cookie policy. Cookie Policy.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT